Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Generic Use Rate at 66.4% in October-December: JGA
March 31, 2017
- Wholesalers to Address Product Return Issue after Fake Harvoni Case: JPWA Chair
March 28, 2017
- Vaccine Association to Standardize Presentation of Expiration Dates above Inspection Dates on Outer Packaging
March 27, 2017
- FPMAJ to Keep Ex-Bureaucrat Kimura as Director General to Secure Lobbying Continuity
March 24, 2017
- JPMA Reprimands Celgene over Side Effect Reporting Violation
March 24, 2017
- Use “Specified Clinical Research” Data for Drug Approval: Regulatory Science Society
March 23, 2017
- Study Group Presents Proposal for Future Vision for Kampo Medicines
March 21, 2017
- Industry Wants Real-World Data to Serve as Grounds for Drug Pricing: JPMA Head
March 7, 2017
- EFPIA Japan to Compile Policy Proposal on Pricing Reform by Early April: New Chair
March 1, 2017
- 3 Groups to Draw Up Guidelines on Inter-Pharmacy Drug Transactions by March-End
February 27, 2017
- US Exclusion from Foreign Price Adjustment Should Be Carefully Considered: PhRMA Japan Chief
February 2, 2017
- JMA Calls for Tighter Penalties on Parties Involved in Counterfeits
January 26, 2017
- JPMA Sets Up New Unit as Liaison for APAC
January 20, 2017
- NPhA Instructing Member Pharmacies on Careful Drug Purchases after Fake Harvoni Issue: Chief
January 20, 2017
- JGA Head Frets Majority of Products Subject to Gap-Year Revisions Will Be Generics
January 20, 2017
- We Must Redouble Efforts for Proper Drug Distribution, Pharmacist Group Says on Fake Harvoni Issue
January 19, 2017
- OTC Industry Group Keen on Expanding Self-Medication Tax Break: Chief
January 18, 2017
- JPMA Eager for Its Active Involvement in Drug Pricing Debates: Chief
January 18, 2017
- JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs
January 18, 2017
- JGA Corrects Generic Share Data for Past 3 Years; July-Sept. Share at 65.1%
January 16, 2017
ページ
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…